Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Accured Expenses (2024 - 2025)

Historic Change in Accured Expenses for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$367000.0.

  • Prelude Therapeutics' Change in Accured Expenses fell 11755.14% to -$367000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$898000.0, marking a year-over-year change of. This contributed to the annual value of -$808000.0 for FY2024, which is 13203.81% down from last year.
  • Per Prelude Therapeutics' latest filing, its Change in Accured Expenses stood at -$367000.0 for Q3 2025, which was down 11755.14% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Prelude Therapeutics' Change in Accured Expenses peaked at $2.1 million during Q3 2024, and registered a low of -$5.7 million during Q1 2024.